Development asset linked to Lei Li in public FDA and regional records.
pharma · Recurrent Cervical Carcinoma
Lei Li
Lei Li drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 3
- Patents
- 0
Lei Li pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Lei Li drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Lei Li in public FDA and regional records.
-
Development asset linked to Lei Li in public FDA and regional records.